OncoGenex to begin Spruce clinical trial to evaluate lung cancer agent
The randomized, Phase 2 study sponsored by SCRI will evaluate if the addition of OGX-427 to carboplatin and pemetrexed therapy can extend progression-free survival (PFS) outcomes. The study
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.